公开(公告)号：JPH11508129A

公开(公告)日：1999-07-21

申请号：JP50032497

申请日：1996-06-06

Applicant: UNIV AMSTERDAM

IPC: G01N33/50 ,  A23C9/00 ,  A23C19/00 ,  A61K8/00 ,  A61K8/66 ,  A61K8/96 ,  A61K38/00 ,  A61K38/46 ,  A61K38/47 ,  A61K39/00 ,  A61P31/00 ,  A61Q11/00 ,  C07K7/06 ,  C07K16/40 ,  C12N1/21 ,  C12N5/10 ,  C12N9/24 ,  C12N9/42 ,  C12N15/09 ,  C12N15/56 ,  C12P19/26 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/577 ,  A61K7/00 ,  A61K7/16

公开(公告)号：KR20180018537A

公开(公告)日：2018-02-21

申请号：KR20177035416

申请日：2016-05-04

Applicant: VRIJE UNIV AMSTERDAM

Inventor： WISMEIJER DANIEL

IPC: A61C8/00 ,  A61B6/14 ,  A61B34/10 ,  A61C1/08 ,  A61C3/02

CPC classification number: A61C3/02 ,  A61C1/084 ,  A61C13/0004

Abstract: 치아임플란트를수용하기위한절골술부위를준비하는툴링, 특히드릴및/또는절골도를맞춤제작하기위한방법. 이방법은, 절골술부위및 그주변의턱뼈영역의계획된위치를모델링하는스캔데이터를수신하는단계와, 스캔데이터에기초하여치아임플란트의가상임플란트모델을생성하는단계와, 가상임플란트모델에기초하여툴링의가상툴링모델을생성하는단계와, 가상툴링모델에기초하여툴링을컴퓨터지원제작하는단계를포함한다.

Abstract translation: 制备工具，特别是钻头和/或截骨术的方法，用于制备用于接纳牙齿植入物的截骨部位。 该方法包括接收扫描数据以模拟截骨部位和周围颚骨区域的计划位置，基于扫描数据生成该牙齿植入物的虚拟植入物模型， 基于虚拟工具模型创建工具模型的工具模型;

公开(公告)号：WO2011105901A3

公开(公告)日：2011-12-01

申请号：PCT/NL2011050131

申请日：2011-02-23

Applicant: AZ UNIV AMSTERDAM ,  FLUITER KEES ,  BAAS FRANK

Inventor： FLUITER KEES ,  BAAS FRANK

IPC: C12N15/113 ,  A61K31/7088 ,  A61K31/712 ,  A61P37/06

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K31/712 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341

Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement component 9 (C9). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal.

Abstract translation: 公开了旨在抑制或阻断哺乳动物补体成分9（C9）的表达的拮抗剂​​。 本发明具有广泛的用途，包括用于制备用于增强哺乳动物急性或慢性神经损伤后神经再生的药物。

公开(公告)号：WO2009028945A3

公开(公告)日：2009-04-16

申请号：PCT/NL2008050575

申请日：2008-08-29

Applicant: AZ UNIV AMSTERDAM ,  PIEK JAN JACOB ,  VAN ROYEN NIELS ,  SCHIRMER STEFAN HENRIK

Inventor： PIEK JAN JACOB ,  VAN ROYEN NIELS ,  SCHIRMER STEFAN HENRIK

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in a subject suffering from insufficient arteriogenic capacity. These nucleic acids are among other useful in methods for diagnosing insufficient arteriogenic capacity, treating a subject suffering from insufficient arteriogenic capacity and/or stimulating arteriogenic capacity and/or stimulating arteriogenesis.

Abstract translation: 本发明涉及由其编码的核酸和多肽，其表达在患有动脉生成能力不足的受试者中调节。 这些核酸可用于诊断动脉生成能力不足的方法，治疗患有动脉生成能力不足和/或刺激动脉生成能力和/或刺激动脉生成的受试者。

公开(公告)号：WO2004048408A3

公开(公告)日：2004-07-29

申请号：PCT/NL0300831

申请日：2003-11-25

Applicant: AZ UNIV AMSTERDAM ,  PEPPELENBOSCH MAIKEL PETRUS ,  ZIVKOVIC DANICA ,  DIKS SANDER ,  BINK ROBERT JOZEF

Inventor： PEPPELENBOSCH MAIKEL PETRUS ,  ZIVKOVIC DANICA ,  DIKS SANDER ,  BINK ROBERT JOZEF

IPC: C07K14/47 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/0797 ,  C12N5/06 ,  C07K14/435 ,  C07K14/46

CPC classification number: C12N5/0623 ,  C07K14/47 ,  C12N2501/40 ,  C12N2501/41

Abstract: The present invention relates to methods for expansion of stem or progenitor cells. These methods rely on Asb-a polypeptides or nucleic acids to temporarily suppress differentiation of the cells, thus allowing proliferation and self-renewal of the stem or progenitor cells. Abs-a polypeptides and coding sequences define a class of polypeptides and nucleic acids that are both structurally and functionally highly conserved among vertebrates. Asb-a polypeptides contain 6 ankyrin repeats and a SOCS box that mediate the effect of the polypeptide on the regulation of specific subsets of genes involved in differentiation. The invention discloses various methods to increase the intracellular concentration of an Asb-a polypeptide for suppression of terminal differentiation of the stem or progenitor cells. The invention further relates to Asb-a polypeptides and nucleic acids, vectors and host cells for use in methods for their production and for use in the method for expansion of stem or progenitor cells, as well as to stem or progenitor cells containing exogenous Asb-a polypeptides and nucleic acids.

Abstract translation: 本发明涉及用于扩增干细胞或祖细胞的方法。 这些方法依赖于Asb-a多肽或核酸来暂时抑制细胞的分化，从而允许干细胞或祖细胞的增殖和自我更新。 Abs-多肽和编码序列限定了在脊椎动物中在结构和功能上高度保守的一类多肽和核酸。 Asb-a多肽含有6个锚蛋白重复序列​​和SOCS盒，其介导多肽对参与分化的基因特异性亚基的调控的影响。 本发明公开了增加用于抑制干细胞或祖细胞末端分化的Asb-a多肽的细胞内浓度的各种方法。 本发明进一步涉及Asb-a多肽和核酸，载体和宿主细胞，用于其生产方法和用于扩增干细胞或祖细胞的方法，以及含有外源Asb- 多肽和核酸。

公开(公告)号：WO0185941A9

公开(公告)日：2003-01-16

申请号：PCT/NL0100361

申请日：2001-05-11

Applicant: AZ UNIV AMSTERDAM ,  VERSTEEG ROGIER ,  CARON HUBERTUS NICOLAAS

Inventor： VERSTEEG ROGIER ,  CARON HUBERTUS NICOLAAS

IPC: G01N33/50 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/47 ,  C12N15/09 ,  C12N15/12 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15

CPC classification number: C07K14/47 ,  C12Q1/6809 ,  C12Q1/6837 ,  C12Q1/6886 ,  C12Q2600/136

Abstract: The invention relates to the treatment and diagnosis of cancer and to the development of drugs. The invention provides a catalogue of >350 targets of the myc oncogene family. The invention provides the insight that it is the myc oncogene family itself that provides for the recruitment and adaptation of the in essence normal physiological mechanisms and events to support the essentially neoplastic character of a cancer cell. Herewith the invention provides a method for the treatment of cancer comprising modulating a myc-dependent downstream gene. The invention also provides a method to use one or more gene products of myc-downstream genes as readout in screenings assays to identify drugs. The insight provided by the invention that myc boosts the cellular protein synthesis machinery can be used to optimise cellular production systems for recombinant protein synthesis systems.

Abstract translation: 本发明涉及癌症的治疗和诊断以及药物的开发。 本发明提供了myc致癌基因家族的> 350个目标的目录。 本发明提供了一种认识，即它是myc致癌基因家族本身，其规定了本质上正常生理机制和事件的募集和适应，以支持癌细胞的基本上肿瘤特征。 本发明提供了一种治疗癌症的方法，包括调节myc依赖性下游基因。 本发明还提供了一种使用myc-下游基因的一种或多种基因产物作为筛选测定中的读出来鉴定药物的方法。 本发明提供的洞察，myc可以促进细胞蛋白质合成机制，可用于优化重组蛋白质合成系统的细胞生产系统。

公开(公告)号：WO0185941A2

公开(公告)日：2001-11-15

申请号：PCT/NL0100361

申请日：2001-05-11

Applicant: AZ UNIV AMSTERDAM ,  VERSTEEG ROGIER ,  CARON HUBERTUS NICOLAAS

Inventor： VERSTEEG ROGIER ,  CARON HUBERTUS NICOLAAS

IPC: G01N33/50 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/47 ,  C12N15/09 ,  C12N15/12 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  C12P21/02 ,  G01N33/68

CPC classification number: C07K14/47 ,  C12Q1/6809 ,  C12Q1/6837 ,  C12Q1/6886 ,  C12Q2600/136

Abstract: The invention relates to the treatment and diagnosis of cancer and to the development of drugs. The invention provides a catalogue of >350 targets of the myc oncogene family. The invention provides the insight that it is the myc oncogene family itself that provides for the recruitment and adaptation of the in essence normal physiological mechanisms and events to support the essentially neoplastic character of a cancer cell. Herewith the invention provides a method for the treatment of cancer comprising modulating a myc-dependent downstream gene. The invention also provides a method to use one or more gene products of myc-downstream genes as readout in screenings assays to identify drugs. The insight provided by the invention that myc boosts the cellular protein synthesis machinery can be used to optimise cellular production systems for recombinant protein synthesis systems.

Abstract translation: 本发明涉及癌症的治疗和诊断以及药物的开发。 本发明提供了myc致癌基因家族的> 350个目标的目录。 本发明提供了一种认识，即它是myc致癌基因家族本身，其规定了本质上正常生理机制和事件的募集和适应，以支持癌细胞的基本上肿瘤特征。 本发明提供了一种治疗癌症的方法，包括调节myc依赖性下游基因。 本发明还提供了一种使用myc-下游基因的一种或多种基因产物作为筛选测定中的读出来鉴定药物的方法。 本发明提供的洞察，myc可以促进细胞蛋白质合成机制，可用于优化重组蛋白质合成系统的细胞生产系统。

公开(公告)号：WO0153834A2

公开(公告)日：2001-07-26

申请号：PCT/NL0100036

申请日：2001-01-18

Applicant: UNIV AMSTERDAM ,  OTTE ARIE PIETER

Inventor： OTTE ARIE PIETER

IPC: G01N33/574

CPC classification number: G01N33/57496

Abstract: The invention relates to a method for detecting a pathological defect in a cell by means of an antibody. According to the invention, an antibody is used which is specific for i) a protein of a Polycomb group complex; ii) a corepressor or a coactivator of a Polycomb group complex; or iii) a Boundary element-binding protein. Preferably the extent of binding of the antibody is compared with a reference value determined for a normal cell of that type. An abnormal concentration of a protein, and hence a different reference value, has been found to be a very good indicator for detecting a pathological defect, such as cancer.

Abstract translation: 本发明涉及通过抗体检测细胞病理缺陷的方法。 根据本发明，使用抗体，其特异于i）Polycomb组合物的蛋白质; ii）Polycomb组合物的共抑制剂或共激活剂; 或iii）“边界”元件结合蛋白。 优选将抗体的结合程度与为该类型的正常细胞确定的参考值进行比较。 已经发现蛋白质的异常浓度，因此具有不同的参考值，这是检测诸如癌症的病理缺陷的非常好的指标。

公开(公告)号：WO9906440A8

公开(公告)日：1999-04-15

申请号：PCT/NL9700449

申请日：1997-07-31

Applicant: AZ UNIV AMSTERDAM ,  APPELMELK BERNARD J ,  ABRAHAM PHILIP R ,  DEVENTER SANDER J H VAN

Inventor： ABRAHAM PHILIP RICHARD ,  APPELMELK BERNARD JAN ,  VAN DEVENTER SANDER JAN HENDRI

IPC: G01N33/53 ,  A61K38/00 ,  A61P31/00 ,  C07K1/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/47 ,  C07K17/00 ,  G01N33/566 ,  G01N33/579 ,  A61K38/10 ,  A61K38/16 ,  G01N33/68

CPC classification number: G01N33/579 ,  A61K38/00 ,  C07K14/4723 ,  C07K14/4742

Abstract: A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable alpha -helix and has the following structure comprising at least 12 amino acids: R1-R2-A1-B1-(A2-B2-C1-A3)m-(C2)n-R3, wherein A = an amino acid selected from the basic amino acids Lys, Arg or His; B = an amino acid selected from the aromatic amino acids Phe, Trp or Tyr; C = an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala; and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-n of the repetitive sequence motifs (A2-B2-C1-A3) have the retro orientation and the remaining repetitive motifs (A2-B2-C1-A3) have the orientation as presented in the formula and wherein, R1-R2- and R3 are a number of amino acids, said number ranging from 0-15 for each of the combination of R1 and R2 and for R3 and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in treatment or diagnosis related to i.a. parasite infection topical and systemic tumors and septic shock.

Abstract translation: 具有氨基酸组成的肽，使得肽是两亲性的，阳离子的并形成稳定的α-螺旋，并具有包含至少12个氨基酸的以下结构：R1-R2-A1-B1-（A2-B2-C1-A3 ）m-（C 2）n -R 3，其中A =选自碱性氨基酸Lys，Arg或His的氨基酸; B =选自芳族氨基酸Phe，Trp或Tyr的氨基酸; C =选自疏水性氨基酸Leu，Ile，Val或Ala的氨基酸; 并且所述肽具有根据式的取向或其反向取向，其中至少0-n个重复序列基序（A2-B2-C1-A3）具有复制取向和剩余的重复基序（A2-B2 -C1-A3）具有式中所示的取向，并且其中R1-R2-和R3是多个氨基酸，对于R 1和R 2以及R 3的组合中的每一个，所述数目为0-15，并且其中 m = 1-10，优选2-8，更优选2-5和n = 1-3，药物组合物包含其在治疗或诊断中与ia相关的这种肽应用 寄生虫感染局部和全身肿瘤和败血性休克。

公开(公告)号：WO2010057994A2

公开(公告)日：2010-05-27

申请号：PCT/EP2009065584

申请日：2009-11-20

Applicant: UNIV AMSTERDAM ,  TIMMERMAN DOLF ,  GREGORKIEWICZ TOMASZ ,  DE BOER WIETEKE DINY ANTONIUS

Inventor： TIMMERMAN DOLF ,  GREGORKIEWICZ TOMASZ ,  DE BOER WIETEKE DINY ANTONIUS MARIA

IPC: H01L31/0352

CPC classification number: H01L31/0352 ,  H01L31/028 ,  H01L31/072 ,  H01L31/0725 ,  Y02E10/547

Abstract: A photovoltaic device is provided comprising a thin-film of an energy conversion material. The energy conversion material includes one or more quantum structures, where the quantum structures comprise a semiconductor material having an indirect band-gap in the bulk. The average size of the quantum structures is selected such that a direct and an indirect band-gaps are modified in the semiconductor material such that the direct band-gap provides charge carrier generation when the quantum structures are exposed to light.

Abstract translation: 提供一种包括能量转换材料的薄膜的光伏器件。 能量转换材料包括一个或多个量子结构，其中量子结构包括在体内具有间接带隙的半导体材料。 量子结构的平均尺寸被选择为使得直接和间接带隙在半导体材料中被修改，使得当量子结构暴露于光时，直接带隙提供电荷载流子的产生。